Compare BioNTech SE - ADR (BNTX) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Huntington Ingalls Industries Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Huntington Ingalls Industries Inc trades at $326 (market cap $12.92B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | HII | |
|---|---|---|
Market Cap | $23.31B | $12.92B |
Sector | Health | Technology |
52-Week High | $119.34 | $453.73 |
52-Week Low | $83.89 | $265.40 |
Enterprise Value | $6.60B | $15.84B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
HII trades at $326.80, down 1.21% over the past day, with a bullish technical outlook supported by moving averages and key support at $326. The company reported strong Q2 2026 earnings of $5.27 EPS, beating estimates, with revenue growth of 10.9% year-over-year. Recent contract awards, including a $2.2 billion task order for surveillance and intelligence capabilities, highlight ongoing government demand. Valuation metrics show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
The investment outlook is positive, driven by robust defense contracts and operational improvements, with a consensus price target of $359.67 suggesting 10% upside. Risks include dependence on U.S. military spending and potential political headwinds affecting naval budgets. Analyst sentiment is mixed but leans bullish, with 44% buy ratings. Overall, HII presents a solid opportunity in the defense sector, though investors should monitor contract execution and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
